LA Private

October 2023

Immutep (ASX:IMM) reports 71.4% response rate for lung cancer therapy

Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company’s drug candidates, highlighting promising data from the  2023 ESMO Congress. Paul Sanger: I’m Paul Sanger for the Finance News Network, and today we’re talking with Immutep (ASX:IMM), and they have a market cap of $380m. Immutep is a clinical-stage biotech company

Immutep (ASX:IMM) reports 71.4% response rate for lung cancer therapy Read More »

US Fed holds steady

Even though the economy is booming and job growth continues, inflation is slowing, leading the US Federal Reserve to refrain from raising interest rates this week. The Fed’s favored PCE inflation reading for September saw a slight increase, but rates are expected to remain unchanged after the two-day meeting early Thursday morning, Sydney time. There’s

US Fed holds steady Read More »

Buffett’s moves raise questions

In the world of investing, Warren Buffett’s recent buying and selling activity has prompted discussions about his current investment strategy. After a four-month hiatus, Buffett’s Berkshire Hathaway has re-entered the market by acquiring over 4 million shares of Occidental Petroleum in the past week. Filings with the US Securities and Exchange Commission, disclosed last week,

Buffett’s moves raise questions Read More »

Investors react to IGO’s quarterly report amid lithium market uncertainty

Investors had a strong reaction yesterday to IGO’s (ASX:IGO) quarterly report, driven by concerns about the volatile outlook for lithium. IGO’s shares initially plunged by 11% in early trading, but by 11:30 am, the decline had reduced to just over 4%. This reaction was expected, given warnings from other lithium players like Pilbara Minerals about

Investors react to IGO’s quarterly report amid lithium market uncertainty Read More »